Agenus Inc. (AGEN)

NASDAQ: AGEN · USD

$7.10

+0.45 (+6.8%)· Recorded snapshot

Market cap	319.6M
Revenue (ttm)	132.7M
Net income (ttm)	91.8M
EPS (ttm)	$2.51
Shares out	45M
P/E (trailing)	2.8x
Volume	622,911
Beta	1.32

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 132.7M
Net income (ttm): 91.8M
EPS (ttm): $2.51
P/E (trailing): 2.8x
Market cap: 319.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E2.8

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AGEN indicators

Market & fundamental data

Available fields

216

Groups with data

Currency

USD

Showing 216 of 216 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001098972
Company name	Agenus Inc.
Country	United States
Country code	US
CUSIP number	00847G804
Earnings date	2026-11-05
Earnings time	bmo
Employees	81
Employees change	-235
Employees growth	-74.37%
Enterprise value	$341.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2000-02-04
Is primary listing	Yes
Is SPAC	No
ISIN number	US00847G8042
Last 10-K release date	2026-03-16
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2024-04-12
Last stock split type	Reverse
Market cap	$319.6M
Market cap category	Micro-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$7.10
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	AGEN
U.S. state	Massachusetts
Website	https://www.agenusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	35.29%
EV/Earnings	3.58x
EV/EBIT	9.16x
EV/EBITDA	8.1x
EV/Sales	2.48x
FCF / EV yield	-29.96%
FCF yield	-32.1%
Forward EV/Sales	3.54x
Forward P/S	3.31x
P/E ratio	2.83x
P/S ratio	2.31x
Price/EBITDA ratio	7.56x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	27.04%
EBITDA margin	30.6%
Gross margin	113.61%
Operating margin	27.04%
Pretax margin	69.29%
Profit margin	69.34%
Profit per employee	$1.1M
Revenue per employee	$1.6M
ROA	12.53%
ROA (5Y)	-16.15%
ROCE	-60.69%
SBC / revenue	8.6%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	12
EPS growth years	0
Gross profit growth	24.04%
Net income growth quarters	7
Net income growth years	2
Revenue growth	30.47%
Revenue growth (Q)	34.36%
Revenue growth (QoQ)	2.32%
Revenue growth 10Y	17.24%
Revenue growth 3Y	10.13%
Revenue growth 5Y	14.12%
Revenue growth quarters	5
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$0
Depreciation and amortization	$4.7M
EBIT	$35.9M
EBITDA	$40.6M
EPS	$2.51
FCF per share	$-2.19
Financing cash flow	$35.7M
Free cash flow	$-98.5M
Free cash flow minus SBC	$-109.9M
Gross profit	$150.8M
Investing cash flow	$70.1M
Net borrowing	$-2.1M
Net cash flow	$7.3M
Net income	$91.8M
Operating cash flow minus SBC	$-109.9M
Operating income	$35.9M
Revenue	$132.7M
Stock-based compensation	$11.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-16.78
Book value per share	$-4.67
Debt / EBITDA	0.81
Goodwill	$24.1M
Interest coverage	0.6
Long-term assets	$93.9M
Long-term liabilities	$146.7M
Net cash (debt)	$-22M
Net cash / market cap	-7.16%
Net debt / EBITDA	0.54
Piotroski F-Score	4
Property, plant and equipment	$21.5M
Shareholders' equity	$-205.9M
Tangible book value	$-226M
Tangible book value per share	$-5.30
Total assets	$172.7M
Total cash	$18.7M
Total debt	$40.7M
Total liabilities	$378.5M
WACC	23.7%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.74
Current assets	$78.8M
Current liabilities	$231.8M
Current ratio	0.34
Net working capital	$-140.6M
Quick ratio	0.32
Working capital	$-153M
Working capital turnover	-0.71

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-51%
Dividend yield	0%
Shareholder yield	-51%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-91.94%
10Y return CAGR	-22.12%
10Y total return	-91.79%
150-day SMA	$5.45
15Y price change	-87.45%
15Y return CAGR	-12.81%
15Y total return	-87.21%
1D price change	6.77%
1M price change	-18.27%
1M total return	-18.27%
1W price change	8.72%
1W total return	8.72%
1Y price change	68.19%
1Y return CAGR	68.25%
1Y total return	68.19%
20-day SMA	$7.05
200-day SMA	$4.91
20Y price change	-97.23%
20Y return CAGR	-16.34%
20Y total return	-97.18%
3M price change	13.87%
3M total return	13.87%
3Y price change	-55.41%
3Y return CAGR	-23.59%
3Y total return	-55.41%
50-day SMA	$7.62
50-day SMA vs 200-day SMA	50over200
52-week high	$10.31
52-week high date	2026-09-30
52-week low	$2.71
52-week low date	2026-02-05
5Y price change	-90.84%
5Y return CAGR	-37.77%
5Y total return	-90.67%
6M price change	70.66%
6M total return	70.66%
All-time high	$8,580.00
All-time high date	2000-02-07
All-time low	$1.38
All-time low date	2025-04-07
Average true range (ATR)	$0.53
Average volume	919.5K
Beta (1Y)	1.23
Beta (2Y)	1.98
Beta (5Y)	1.32
Change from 52-week high	-31.13%
Change from 52-week low	161.99%
Change from all-time high	-99.92%
Change from all-time low	405.8%
Change from open	8.56%
Day's gap	-1.65%
Dollar volume	$4.4M
High price	$7.10
Low price	$6.53
Monthly RSI	47.29
Open price	$6.54
Position in 52-week range	100%
Premarket change	-0.13%
Premarket close	$6.65
Premarket price	$6.64
Previous close	$6.65
Price vs 150-day SMA	28.05%
Price vs 20-day SMA	-0.94%
Price vs 200-day SMA	42.27%
Price vs 50-day SMA	-8.42%
Relative volume	0.68
RSI	48.48
Sharpe ratio	0.91
Sharpe ratio (3Y)	0.29
Sharpe ratio (5Y)	-0.02
Sortino ratio	1.84
Sortino ratio (3Y)	0.51
Sortino ratio (5Y)	0.02
Volume	622.9K
Weekly RSI	55.14
YTD price change	122.29%
YTD total return	122.29%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	40.2M
Float percentage	89.35%
Shares change (QoQ)	7.97%
Shares change (YoY)	51%
Shares held by insiders	1.48%
Shares held by institutions	40.06%
Shares outstanding	45M
Short % of float	16.95%
Short % of shares	15.15%
Short ratio	6.5 days

Deeper analysis on AGEN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AGEN report

Is a complete AGEN research report available?

No complete published report is available for Agenus Inc. (AGEN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Agenus Inc. (AGEN)

Price

Financial snapshot

Fair-value bridge

Latest news · AGEN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AGEN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AGEN

Frequently asked questions